Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE)

Closed Solicitation Posted

Solicitation number
CBD254-012
Agency
Responses due
Set-aside
Total Small Business

Opportunity facts

More information

Notice details come from DoD SBIR/STTR (DSIP). Updated .

About this opportunity

The Department of the Army Acquisition Support Center's Joint PEO Chemical and Biological Defense seeks Phase I SBIR proposals under topic CBD254-012, Microphysiological Systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE), with proposals due May 13, 2026, a date that precedes the current date. The set-aside is Total Small Business. The statement of objectives describes the work as a Defense Threat Reduction Agency research and development effort supporting the Joint Science and Technology Office. The topic is part of the FY25.4 Chemical and Biological Defense Program SBIR Release 12, and proposals must be submitted through the Defense SBIR/STTR Innovation Portal (DSIP).

Phase I requires developing or refining an immune microphysiological system (iMPS) that recapitulates the immunogenicity and efficacy of an FDA-approved vaccine against a viral pathogen, with standardized data outputs comparable to existing preclinical and clinical data. Phase I prohibits research involving human subjects, animal subjects, or recombinant DNA. Such research may be proposed for Phase II and requires DoD-level approvals separate from institutional review boards. All offerors must disclose foreign nationals, green card holders, and dual citizens involved in the project, including country of origin, visa or work permit type, and anticipated involvement level. No CMMC level requirement applies. Phase II forecasts performance of novel vaccine constructs and delivers standard operating procedures, training materials, and standardized datasets. Phase III evaluates route of administration, dose optimization, booster frequency, and off-target effects through multi-organ systems.

Phase I awards are limited to $209,575 for periods of performance up to six months. Direct to Phase II base amounts cannot exceed $698,582.50 for 12 months, with an optional 12-month extension not to exceed $1,397,165.00 total. Phase II awards typically use cost-plus fixed fee contracts at the Contracting Officer's discretion. Phase I proposals are evaluated on three criteria specified in the DoD SBIR Program BAA, and selection notifications occur within 90 days of BAA closure. The technical volume may not exceed 20 pages in 10-point minimum font. Direct to Phase II proposals add a Feasibility Documentation section of up to 5 pages and a Technical Proposal of up to 20 pages. Firms should register with DCAA-approved accounting systems before Phase II.

The NAICS code is 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and the PSC is AC12, National Defense R&D Services. No technical point of contact is listed.

Notice text

DoD SBIR topic CBD254-012

Component: CBD

Command: CBD

Phase: SBIR Program Phase I Action

Technology Areas: Bio Medical; Chem Bio Defense

Focus Areas: Biotechnology

Keywords: Microphysiological system; New Alternative Methodologies; Medical Countermeasures; Vaccines; Immunogenicity

ITAR: No

Objective:

Develop an immune microphysiological systems (iMPS) for the evaluation and development of vaccines against high consequence pathogens. iMPS may include, but are not limited to, immune organoid, organ-tissue equivalent, microfluidic chips, or similar systems as well as single or multiple organ models.

Description:

The Defense Threat Reduction Agency (DTRA) Research and Development Chemical and Biological Technologies Directorate Medical division in support of the Joint Science and Technology Office (JSTO) is charged with addressing the potential threat to the armed services posed by a wide range of pathogenic and toxic agents. In support of warfighter readiness, vaccines build a defense against known and future threats. However, the development of vaccines is stymied by traditional in vitro or in vivo models, which are slow and do not fully recapitulate the complexity of the human immune system. As a result, promising preclinical data do not necessarily translate to successful human clinical trials. This disconnect inhibits rapid response against new and emerging threats to the Warfighter.

iMPS have the potential to model the human immune response in vitro, providing a route to accelerated discovery and validation of medical countermeasures by offering a bridge between preclinical studies and advanced development. Successful iMPS should (1) recapitulate immunogenicity and efficacy of a known vaccine, (2) differentiate between vaccines with variable efficacy against the same threat, and (3) predict immunogenicity of novel vaccine constructs. It would also be beneficial if iMPS could evaluate the optimal vaccine dose, schedule, and route of administration as well as predict off-target effects of a vaccine. Additionally, the data output of ideal iMPS should be standardized so that they may be compared to existing animal models and/or clinical data. Eventually, iMPS would be utilized to assess vaccine immunogenicity and efficacy against DoD pathogens of concern in a high containment environment and ultimately, would greatly facilitate vaccine development and support Warfighter readiness.

Phase I:

The objective of Phase I is to develop an iMPS or refine an existing iMPS and demonstrate that it is capable of recapitulating the immunogenicity and efficacy of an FDA-approved vaccine against a viral pathogen. The iMPS should be capable of key functions of the innate and adaptive immune systems and data outputs should be standardized to enable comparison to existing preclinical and clinical data. Success will be measured by comparing the iMPS-produced data to existing clinical data. This phase aims to establish the foundational validity of the iMPS as a reliable tool for vaccine evaluation.

Phase II:

Phase II moves beyond replicating known vaccine responses to actively forecasting the performance of new vaccines before in vivo studies or clinical trials. It will leverage the iMPS developed or refined in Phase I to predict the immunogenicity and efficacy of novel vaccine constructs against pathogens of concern for the DoD. When available, iMPS-produced data should be compared to preclinical in vitro or in vivo data. To ensure the reproducibility and consistency of results across different laboratories and users, Standard Operating Procedures (SOPs) for the operation and maintenance of the iMPS should be developed and if necessary for the operation of the iMPS, comprehensive training materials should also be created. Deliverables will be iMPS SOPs and training materials as well as standardized datasets and summary reports on each vaccine construct tested.

Phase III:

PHASE III: This phase focuses on broadening the iMPS's application in vaccine development. Key parameters, such as route of administration, dose optimization, and booster frequency, will be evaluated using the iMPS. Furthermore, the iMPS will be utilized in a multi-organ MPS to assess potential off-target effects of vaccine candidates. The goal is to create a comprehensive iMPS platform capable of informing critical decisions throughout the vaccine development pipeline, reducing reliance on traditional animal models, and accelerating the path to clinical trials

PHASE III DUAL USE APPLICATIONS: Beyond DoD applications, the iMPS developed may be used by commercial biotechnology companies, pharmaceutical companies, academic research labs, and public health organizations to evaluate vaccine immunogenicity and efficacy outside of an animal model, in line with FDA guidance.

Files

File Type Posted
CBD254-012.pdf PDF
CBD_SBIR_25.4_R12.pdf PDF

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors